LSI的动态

?? Thank you to Melissa Barall, CFA, Luba Perry, PhD and Shadi Saberi for participating in the inaugural Founder Pitch Feedback session! Melissa was so generous to share her time and provide feedback to Luba and Shadi on their pitch decks! Melissa is a Venture Partner at Coyote Ventures and an angel investor with Gaingels. Her investment foci include women's health and biohacking. Luba and Shadi have each founded companies in women's health, although with a focus on breast cancer and in adjacent areas of tissue therapeutics and 3D ultrasound scanning. Luba is the Founder of ReConstruct Bio, a startup with a mission to provide a reliable, durable, and safer solution to breast reconstruction and augmentation for breast cancer survivors. Most women with breast cancer undergo some kind of mastectomy to treat their cancer, and 40% choose to have breast reconstruction surgery. However, all currently available reconstruction options come with significant health risks. ReConstruct uses tissue engineering techniques to create living tissue implants from a patient’s own cells for breast reconstruction, effectively developing 3D organ engineering platform technology. Shadi is the Founder and CTO of iSono Health. The ATUSA? system is the world’s first automated and portable 3D breast ultrasound scanner, and has received FDA 510(k) clearance. Scanning the whole breast in only 2 minutes, the ultrasound device provides accessible and personalized imaging at the point of care, assisting clinicians in localizing and classifying breast lesions. iSono Health is currently integrating AI for a fully automated hardware, software, and AI solution to whole breast imaging. #founders #investors #pitching #uplifting #breastcancer #therapeutics #medicaldevice

Congrats to the HistoSonics, Inc. team on raising $102M Series D led by Alpha Wave Global, with participation from new investors Amzak Health and HealthQuest Capital, and existing investors Johnson & Johnson Innovation - JJDC, Inc. (JJDC), Venture Investors, Lumira Ventures, Yonjin Venture, the State of Wisconsin Investment Board and others. Histotripsy is a novel form of focused ultrasound that uses high amplitude, very short pulses to create a “bubble cloud” that is designed to mechanically destroy and liquefy targeted liver tumors. These bubble clouds form and collapse in microseconds, creating mechanical forces strong enough to destroy tissue at cellular and sub-cellular levels in a non-invasive and non-thermal method. Histotripsy offers a promising alternative to treatments such as surgery, radiation and chemotherapy, which often have significant side effects. Read the release: ???? https://lnkd.in/dHzv-K8m

More exciting news, as Myoptechs joins our portfolio!

?? HistoSonics, Inc. Secures $102M Series D Funding, Paving the Way for a New Era in Non-Invasive Surgery ?? Histotripsy is a technology that uses sound energy to precisely target and destroy tissue without incisions, radiation, or heat. This means patients can undergo treatment with minimal recovery time, reducing the risks and complications associated with other surgical methods. Their Edison platform is very impressive and at SRS earlier this year the booth was a crowded place with an impressive demo. As the global population ages, the demand for less invasive, more precise treatment options is only increasing. HistoSonics is answering this call with a technology that not only improves patient outcomes but also allows the surgeon to treat a wider variety of tumor types in the liver, kidney, pancreas, prostate, and even brain tumors. “Histotripsy is a paradigm-changing treatment option for patients who want a non-invasive approach to target and destroy tumors without the need for needles or incisions,” said Mike Blue, President & CEO, HistoSonics. “We’re thrilled to announce this top-tier investor syndicate led by Alpha Wave, which reinforces the confidence in our mission to impact patients’ lives with our current liver application and expanded use in kidney, pancreas, prostate, brain and other tumor types. With Alpha Wave Ventures leading the round, with support from Johnson & Johnson Innovation JJDC Inc, Amzak Capital Management and HealthQuest Capital. ?? Congratulations to the HistoSonics team on this funding.?? #medtech #noninvasivesurgery #innovation #investment #histotripsy #medicaltechnology

Top 5 Reasons To Invest In Cytonics ?? invest.cytonics.com ? Are you ready to join us on our mission to cure osteoarthritis? Time’s up. Let’s go! Our crowdfunding campaign ends TOMORROW, and we couldn’t be more pleased and grateful for all of the support. With over 1,500 new investors and 6,000 shareholders at our backs, we are poised to have a breakout year. ?? Here’s why you should consider investing: ? With over 8,000 patients successfully treated to date, the clinical and commercial success of our first-generation FDA-approved therapy for OA is proof that our core technology is an effective treatment for OA. ?? With over 100 years combined experience in the medical and biotech fields, the Cytonics team possesses the technical competencies to navigate the FDA regulatory framework. This is further evidenced by the FDA approval of our APIC medical device. ?? Our second-generation therapy, “CYT-108” is on the cusp of completely disrupting a $240 billion market for osteoarthritis treatments. If approved by the FDA, “CYT-108” may be the first and only OA therapy capable of actually repairing cartilage and providing lasting relief - The Holy Grail of regenerative medicine. ??? Our intellectual property portfolio includes 24 U.S. and international patents, ensuring a strong competitive edge. ?? You are investing as we advance through our most significant milestone to date - the first-in-human Phase 1 clinical study of CYT-108 as a treatment for OA of the knee. ???? CEO At Your Service: FINAL Investor Webinar ?? May 28, 2024 @ 12pm EST: https://lnkd.in/egVCK-st #biotech #biotechnology #arthritis #osteoarthritis #investing #crowdfunding #venturecapital #healthcare #drugdevelopment #clinicaltrials #regenerativemedicine #orthopedics #orthopaedics #surgery #investor #FDA #medicine #lifesciences #researchanddevelopment #capitalmarkets

Top 5 Reasons To Invest In Cytonics ?? invest.cytonics.com ? Are you ready to join us on our mission to cure osteoarthritis? Time’s up. Let’s go! Our crowdfunding campaign ends TOMORROW, and we couldn’t be more pleased and grateful for all of the support. With over 1,500 new investors and 6,000 shareholders at our backs, we are poised to have a breakout year. ?? Here’s why you should consider investing: ? With over 8,000 patients successfully treated to date, the clinical and commercial success of our first-generation FDA-approved therapy for OA is proof that our core technology is an effective treatment for OA. ?? With over 100 years combined experience in the medical and biotech fields, the Cytonics team possesses the technical competencies to navigate the FDA regulatory framework. This is further evidenced by the FDA approval of our APIC medical device. ?? Our second-generation therapy, “CYT-108” is on the cusp of completely disrupting a $240 billion market for osteoarthritis treatments. If approved by the FDA, “CYT-108” may be the first and only OA therapy capable of actually repairing cartilage and providing lasting relief - The Holy Grail of regenerative medicine. ??? Our intellectual property portfolio includes 24 U.S. and international patents, ensuring a strong competitive edge. ?? You are investing as we advance through our most significant milestone to date - the first-in-human Phase 1 clinical study of CYT-108 as a treatment for OA of the knee. ???? CEO At Your Service: FINAL Investor Webinar ?? May 28, 2024 @ 12pm EST:? https://lnkd.in/egVCK-st #biotech #biotechnology #arthritis #osteoarthritis #investing #crowdfunding #venturecapital #healthcare #drugdevelopment #clinicaltrials #regenerativemedicine #orthopedics #orthopaedics #surgery #investor #FDA #medicine #lifesciences #researchanddevelopment #capitalmarkets

Congratulations Mats Danielsson! The European Innovation Council (EIC) Pathfinder programme has awarded funding to several groundbreaking research projects, including 1MICRON, led by KTH professor Mats Danielsson. The project aims to improve the quality of medical imaging by developing a new high-resolution sensor, making it easier to detect details that current X-ray technology might miss. Today, it can take weeks to analyze medical images, and if cancer cells are found after surgery, patients may need to return for more procedures. The 1MICRON project hopes to speed up this process, offering clearer images faster, which could reduce the need for additional surgeries and improve survival chances for cancer patients. In late July, it was announced that four deep tech research projects involving Kungliga Tekniska h?gskolan will receive a total of €11.7 million. The 1MICRON project is one of these, aiming to make a significant impact in healthcare. #LifeScience #EICPathfinder #MedicalImaging #CancerResearch #DeepTech

We may have unveiled our new brand this week, but the #LSIAlumni are still hitting the same incredible milestones. This week the LSI Alumni raised over $65 million, announced new partnerships, enrolled patients in pivotal trials and much more on the road to #LSIEurope24 Your 60 second news recap: Accelus — Kevin McGann → Announced the addition of two new members to its leadership team: Rob German, Vice President of Research & Development, and Luke Perkins, Senior Director of Product Management. binx health — Jeffrey R. Luber → Raised a $65 million Series F financing round led by Hildred Capital, with participation from EQT Life Sciences. Juniper Biomedical — David Constantine → Raised a $2M oversubscribed Series Seed funding round led by Auroral Holdings, a MedTech focused family office, with participation from Atma Capital, Hub Angels, Beacon Angels and other private investors. Kent Imaging — Pierre Lemire → Announced a partnership with WoundCentrics who will incorporate Kent Imaging's SnapshotNIR as a point-of-care imaging tool. Moon Surgical — Anne Osdoit, Jeffery Alvarez → Expanded its Maestro surgical robot indications to gynecological laparoscopy. The recent gynecological use was for hysterectomy, cystectomy, adnexectomy and ovariectomy procedures. PredxBio — Dusty Majumdar, PhD, S. Chakra Chennubhotla, Craig Cinquina → Announced a strategic partnership with Sirona Dx aimed at reshaping the landscape of drug discovery and development. Protembis GmbH — Karl von Mangoldt → Enrolled the first patient in the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial. Sonder Capital → Announced the appointment of firm Co-founder Kate Garrett as Managing Partner. TeleMeet.live — Kelley Mondesiré, Khash Sarrafi → Announced the appointment of Dr. Omar De La Cruz as Chief Behavioral Officer. Transverse Medical Inc — Eric Goslau → Reorganized its Board of Directors following the recent closing of a Series B1 financing. Vascular Perfusion Solutions, Inc. — Rafael J. Veraza, PhD, MPH → Shared its latest publication, which demonstrated the successful preservation of brain-dead donor human hearts for up to 8 hours using the VP.S ENCORE?. Vektor Medical, Inc. — Robert J. Krummen → Announced the publication of data in the Journal of Cardiovascular Electrophysiology demonstrating vMap’s ability to reduce the time from mapping to treatment, procedure duration, and fluoroscopy when treating cardiac arrhythmia patients with ablation therapy. VESTECK, Inc — Joseph W. Rafferty → Announced the The United States Patent Office has issued the "REMOTE SURGICAL SUTURE SYSTEM" patent for its platform technology. Vitestro — Toon Overbeeke → Formalized a collaboration with Result Laboratorium, to integrate two blood draw devices into the phlebotomy department. Congratulations to all the LSI Alumni who made major news this week!

We are proud to announce that we will lead DeepLook Medical’s Series A funding round. DeepLook Medical, a healthtech company specializing in visual enhancement technology for advanced medical imaging, marks the 11th investment in Xcellerant VC Fund 1. Michael Shufeldt, MBA, Principal at Xcellerant Ventures, will join the board. DeepLook Medical’s DL Precise is the first FDA approved AI-empowered device to detect cancer (and, importantly, reduce false positives) in dense breast tissue. The complexity?of diagnosis with dense breast tissue is so significant that the FDA now requires all women who receive mammograms to be informed whether they have dense breast tissue. Follow this link to read the full press release: https://lnkd.in/ggM-iuKT You can learn more about DeepLook Medical by following them on LinkedIn or heading to their website: https://lnkd.in/e4z2u8YF #seriesa #venturecapital #mammogram #breastcancer #breastcancerscreening #mammography #radiology #healthtech

Interested in biotech #entrepreneurship and don’t know where to begin? We have episodes for that! Our friend Karen Y. Torrejon, founder and CEO of Humonix Biosciences, Inc. is here at Association for Research in Vision and Ophthalmology (ARVO) (Booth #1344), and also is in your ears on “Bench to Boardroom” episode 4! https://lnkd.in/gi69arnK Listen, subscribe, come say hello, and learn!